4.8 Meeting Abstract

A phase Ib/II study of BMS-813160, a CC chemokine receptor (CCR) 2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients (pts) with advanced pancreatic or colorectal cancer

Journal

CANCER RESEARCH
Volume 78, Issue 13, Pages -

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1538-7445.AM2018-CT124

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available